Chad Cowan
Known title: Chief Scientific OfficerCIK: 0002039294
Chad Cowan's purchase track record
Chad Cowan has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/22/2025 | IPSC | $49K | +175.9% | +167.8% | +8.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IPSC | ▼ Sell | Tax Withholding | 358 | $802 | 6/11/2026 | View on chart |
| IPSC | ▼ Sell | Tax Withholding | 1,365 | $3K | 4/1/2026 | View on chart |
| IPSC | ▼ Sell | Tax Withholding | 1,431 | $4K | 3/11/2026 | View on chart |
| IPSC | ▲ Buy | Grant | 135,000 | $0 | 2/2/2026 | View on chart |
| IPSC | ▼ Sell | Tax Withholding | 1,611 | $2K | 1/2/2026 | View on chart |
| IPSC | ▲ Buy | Open Market | 58,060 | $49K | 12/22/2025 | View on chart |
| IPSC | ▼ Sell | Open Market | 5,462 | $3K | 11/20/2025 | View on chart |
| IPSC | ▲ Buy | Grant | 762,543 | $0 | 9/18/2025 | View on chart |
| IPSC | ▲ Buy | Grant | 19,500 | $0 | 3/11/2025 | View on chart |
| IPSC | ▲ Buy | Grant | 74,376 | $0 | 10/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Century Therapeutics faces competitive pressure on key strategy
A recent analysis suggests that competitors are taking steps to reduce the risks associated with Century Therapeutics' primary business focus. This development is relevant as it may impact the company's market position and future prospects. The stock is currently trading near its support levels, reflecting ongoing uncertainty in the market.
Century Therapeutics faces competitive pressure on key strategy. A recent analysis suggests that competitors are taking steps to reduce the risks associated with Century Therapeutics' primary business focus. This development is relevant as it may impact the company's market position and future prospects. The stock is currently trading near its support levels, reflecting ongoing uncertainty in the market.